Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
AssigneeErytech Pharma
InventorsKarine Aguera, Willy Berlier, Fabien Gay, Yann Godfrin
Life of this patent
Estimating the term…
Abstract
The invention is related to a new method for treating liquid and solid cancers, in a mammal, including human, wherein methioninase is administered before asparaginase. The invention also encompasses the use of a dietary methionine deprivation, possibly combined with methioninase administration, in advance of asparaginase treatment. Methioninase and asparaginase may be used in particular under free form, pegylated form or encapsulated into erythrocytes.
Claims9
A method for treating cancer in a mammal in need thereof, the method comprising administering to the mammal in need thereof, a composition comprising a methioninase and then a composition containing an asparaginase, wherein there is a delay of between about 1 h and about 30 days between the end of the methioninase administration and the initiation of the asparaginase administration, and wherein:
- when methioninase is under free form or is pegylated, the delay is between about 1 h and about 7 days, between about 3 h and about 6 days, or between about 1 day and 5 days;
- and
- when methioninase is encapsulated into erythrocytes, the delay is between about 1 day and about 20 days, or between about 1 day and about 10 days.
Dependencies are inferred from the claim text.